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Abstract: Vaccination remains the most effective and essential prophylactic tool against infectious
diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes
remain so far limited. Novel adjuvants may offer a significant advantage in the development of
malaria vaccines, in particular if combined with inherently immunogenic platforms, such as virus-like
particles (VLP). Dioleoyl phosphatidylserine (DOPS), which is expressed on the outer surface of
apoptotic cells, represents a novel adjuvant candidate that may confer significant advantage over
existing adjuvants, such as alum. In the current study we assessed the potential of DOPS to serve
as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP
using Plasmodium falciparum thrombospondin-related adhesive protein (TRAP) as a target antigen.
TRAP was chemically coupled to VLPs derived from the cucumber mosaic virus fused to a universal
T cell epitope of tetanus toxin (CuMVtt). Mice were immunized with TRAP alone or formulated in
alum or DOPS and compared to TRAP coupled to CuMVtt formulated in PBS or DOPS. Induced
immune responses, in particular T cell responses, were assessed as the major protective effector
cell population induced by TRAP. The protective capacity of the various formulations was assessed
using a transgenic Plasmodium berghei expressing PfTRAP. All vaccine formulations using adjuvants
and/or VLP increased humoral and T cell immunogenicity for PfTRAP compared to the antigen
alone. Display on VLPs, in particular if formulated with DOPS, induced the strongest and most
protective immune response. Thus, the combination of VLP with DOPS may harness properties of
both immunogenic components and optimally enhance induction of protective immune responses.
Keywords: vaccine; adjuvants; Plasmodium falciparum; malaria; virus like particle (VLP); dioleoyl
phosphatidylserine (DOPS)
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1. Introduction
Malaria remains a massive challenge for global health [1–3]. According to the World Health
Organization (WHO), the occurrence of 214 million cases and 438,000 deaths caused by malaria
occurred worldwide a few years ago [4]. Five plasmodium species exist that cause malaria in humans,
but only two of them dominate disease: Plasmodium falciparum and Plasmodium vivax [5,6]. Despite these
impressive numbers, up to the present time there is no licensed malaria vaccine for worldwide use
in humans. The flag-ship vaccine against P. falciparum RTS,S/AS01, based on the circumsporozoite
(CSP) antigen, is licensed in a limited way only, mostly due to sometimes disappointing efficacy in
clinical trials [7]. The RTS,S vaccine is well-known to induce strong antibody and Th cell responses;
however induction of CD8+ T cells is usually weak. More recently, an optimized version of RTS,S,
called R21 has entered clinical development with some exciting new properties in preclinical [8] and
clinical trials (unpublished data). R21 comprises only the hybrid CS-HBsAg protein in the VLP with
no additional HBsAg monomers. Nevertheless, overall efficacy may be improved with additional
antigens and adjuvants able to induce strong T cells immunity may also be beneficial for this purpose.
Many antigens have been tested in vaccine development, and a promising, relatively recent,
malaria vaccine candidate is the thrombospondin-related adhesive protein (TRAP), a transmembrane
protein with extracellular adhesive domains essential for sporozoite motility and liver cell invasion [9].
TRAP is thought to be mainly a target for T cell-based vaccines and may therefore an important
addition to those vaccines that already provide protective antibody response. In addition to CD8+
T cells, some studies also indicate an importance of TRAP-specific antibodies as protective effector
mechanism against malaria [10–13].
Even the best potentially protective antigen usually requires the use of a potent adjuvant or
adjuvant system to help focus and develop the immune response to act faster, stronger, and offer
long-term immunity, without compromising safety. Adjuvants can modulate the type of immune cells
triggered and enhance the overall immune response [14]. Since the beginning of the 20th century,
when the first adjuvants (aluminum salts) were tested in humans, the concept of adjuvants has
become an important component of vaccine development and is now a key target for improving
immunogenicity and efficacy of modern vaccines [15]. Aluminum-based preparations (usually
summarized under the term “alum”) remain the most commonly used adjuvants in both human
and veterinary vaccines [16,17], but evidence of the better effectiveness of novel adjuvants for existing
and emerging diseases is continuing to grow.
Alum-based adjuvants have a huge safety record and positive benefit risk profile outweigh
potential concerns in the context of prophylactic vaccination programs. Alum is cost-effective, easy to
manufacture, and licensure of alum formulated products is comparably straightforward. Moreover,
alum has been used effectively in adjuvant systems, combining alum with immunostimulators [18].
However, some more difficult-to-target pathogens, such as malaria, may benefit from a more potent
combination of adjuvants that in particular, would induce more potent Th1 rather than Th2 responses
as well as CD8+ T cell responses. In addition, alum tends to induce less protective IgG subclasses, such
as IgG1 in mice or IgG4 in humans. Hence, if protection is not solely based on pathogen neutralization,
but Fc-receptor interactions and complement are also important, alternative adjuvants may be more
potent than alum [17,19–23].
Phosphatidylserine derivatives are part of a family of related compounds that may differ in
their fatty acid content. They are distributed within the inner leaflet of plasma membranes. During
apoptosis PS derivatives are translocated to the outer membrane where it functions as a surface
signaling molecule, recognized by phagocytic cells such as macrophages [24]. PS derivatives, including
Di-oleoyl-phosphatidyl-serine (DOPS), have been shown to modulate ovalbumin-specific antibody
production in different ways. In these experiments, DOPS significantly increased the production of
IgG subclasses, with no significant effect on IgE production [25,26].
Antigens displayed on VLPs are repetitive and benefit from intrinsic adjuvant properties of
VLPs, resulting in strong B cell responses [27,28]. In addition, VLPs, such as the here employed
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CuMVtt VLP package RNA, which drives Th1 and IgG2a responses in a TLR7/8-dependent manner.
Here we demonstrate that combination with DOPS, but not alum, further enhances these properties
yielding optimal protection upon vaccination with a TRAP-CuMVtt-based vaccine. Hence, we present
a formulation that is built on established pharmaceutical principles combining drug delivery concepts
(VLP) in combination with a second generation adjuvant (immunomodulator) functioned to provide
a means by which immune activation could be better achieved for a vaccine to confer enhanced
protection against malaria.
2. Material and Methods
2.1. PfTRAP Protein Production
The PfTRAP gene (accession number: PF3D7_1335900) was synthesized by Geneart™ with a
His.tag sequence of six histidine amino acids (HHHHHH) at the C-terminal and subsequently cloned
into an expression vector pHLsec at the AgeI and KpnI restriction sites. The new construct AS-807
= PfTRAP-His.tag in pHLsec was transformed into Escherichia coli DH5a bacteria and the growth
of bacterial cultures was purified using QIAGEN Plasmid Mega Kit. The pHLsec-PfTRAP purified
plasmid was transfected into HEK-293T cells for protein production. The supernatant from HEK-293T
cells culture was purified from dialyzed conditioned medium against phosphate-buffered saline (PBS)
buffer by immobilized nickel affinity chromatography, followed by size-exclusion chromatography in
20 mM Tris-HCl, pH 8.0, and 300 mM NaCl.
2.2. Vaccines Preparation
The VLP used to prepare the vaccine by coupling with PfTRAP protein was derived from the
cucumber mosaic virus fused to a universal T cell epitope of the tetanus toxin (CuMVtt) that was
expressed in E. coli BL21 (DE3) Star (Thermo Fisher Scientific) and purified as previously described [10].
The PfTRAP protein was covalently conjugated to VLP using the strategy already published [10].
The conjugated VLP-PfTRAP vaccine was analyzed by SDS-PAGE and Western blot to detect bands
corresponding to the various components of the coupling reaction. The PfTRAP protein was also
used to prepare vaccine based on aluminum hydroxide adjuvant (alum) (InvivoGen, San Diego, USA)
and phosphatidyl serine (PS) derivatives—1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) (Avanti
Polar Lipids, Inc., Alabaster, Alabama, USA).
The vaccine formulation using alum was prepared using 10 µg of Al3+ per dose per mouse
according to the manufacturer’s specifications (InvivoGen, San Diego, CA, USA). The alum was mixed
to PfTRAP protein and vortexed gently for few seconds and incubated at room temperature for one
hour and subsequently vaccinate the mice.
In order to generate PS-DOPS formulated candidate vaccines, PS-DOPS was dissolved in PBS
and mixed to PfTRAP protein or VLP-PfTRAP vaccine and gently vortexed for few seconds. Vaccine
batches were freshly produced for each vaccination.
2.3. Immunization Protocol
In order to check the vaccine efficacy, 6 female BALB/c inbred mice per group and 8 female CD1
outbred mice per group, 6 weeks old, purchased from Harlan, United Kingdom, were vaccinated
intramuscularly (i.m.) with 20 µg (50 µL) per mouse of PfTRAP protein diluted in PBS, mixed with
alum or DOPS adjuvants, chemically coupled to VLP with or without DOPS. The vaccinations were
done 3 times: prime (Day 0), first boost (Day 21), and second boost (Day 42). The samples (blood) were
collected before each vaccination on Days 0, 21, 42, also on Days 50 and 59 to check the humoral and
cellular immunogenicity. On Day 63, three weeks after the second boost, the mice were challenged with
a transgenic P. berghei replacement expressing PfTRAP protein (mutant # 2632 cl1). The determination
of prepatent period (after challenge of immunized mice with transgenic sporozoites) was checked by
counting the level of parasitemia in the blood smears daily beginning on fourth day after the challenge
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until the mice reach 1% parasitemia. The mice that did not show any erythrocytes infected until 14th
day after challenge were considered sterile protected.
2.4. Kinetics of Antibody Production
For assessment of antibody production, total IgG and its subclass, enzyme-linked immunosorbent
assays (ELISAs) were performed. For that, 96-well microtiter ELISA plates (Thermo Scientific,
Nottingham, UK) were coated with 100 µL per well in a concentration of 1 µg/mL of purified PfTRAP
and diluted in carbonate buffer (CBB) 50 mM at pH = 9.6 and incubated overnight at 4 ◦C. In the next
day the plates were filled with 200 µL of 2% BSA-PBS to avoid nonspecific binding and incubated at
room temperature for two hours. The next step, the sera from mice were diluted in 0.2% BSA-PBS
buffer, initially starting with 1 in 100 and followed by eleven 1/3 serial dilution in the ELISA plates.
For the total IgG measurement, 100 µL per well of goat anti-mouse IgG diluted to 1:2000 (Secondary
Antibody, HRP conjugate (ThermoFisher, Paisley, UK) were added and incubated for 1 h at room
temperature. For assessment of IgG subclass, goat anti-mouse IgG subclass (goat anti-mouse IgG1,
IgG2a, IgG2b HRP coupled, Life Technologies) were used in a dilution of 1:2000, and incubated for
1h at room temperature. Between all the previous steps the ELISA plates were washed by filling the
wells four times with 200 µL PBS—0.05% Tween and 200 µL PBS. To develop the reaction, 100 µL/well
of TMB substrate (Sigma-Aldrich) was applied and incubated at RT for 10 min and under aluminum
foil for light protection. After that, the reaction was stopped by adding 100 µL/well of 0.5 M H2SO4
(sulfuric acid) and the plates read using microplate reader at 450 nm. The titers are expressed as
dilutions leading to half-maximal OD (OD50).
2.5. Assessment of TCD4 Cells Polarization
The evaluation of CD4+ T cell polarization was made by detection of TNFα, IFNγ (Th1 cytokines)
and IL-4 (Th2 cytokine) using sera collected on Day 50 (1 week after the second boost) by multiplex
assays. The goal was to determine whether differences in serum cytokine profile exist between
unvaccinated and vaccinated mice with PfTRAP coupled to VLP with or without DOPS adjuvants,
as well as to compare the adjuvants DOPS vs. alum in term of Th1 and Th2 cytokines stimulations.
The methodology applied was that described by MHSTCMAG-70K kit guidelines of MILLIPLEX MAP
Mouse High Sensitivity T Cell Panel. Briefly, all reagents from the kit were brought to room temperature
and vortexed before adding to the plate provided with the kit. After that, the antibody-immobilized
beads were prepared in the mixing bottle, as well as the quality controls, serum matrix and standards.
The sera from vaccinated and nonvaccinated mice were defrosted completely and spin to avoid
particulates. The sera samples were diluted 1:2 using assay buffer and used 25 µL per well, two wells
per sample. The immunoassay procedure consisted adding 50 µL of standard 1–7 and 50 µL of serum
matrix to background (standard 0). Followed by adding 25 µL assay buffer to sample wells, plus
25 µL serum to all sample wells. Twenty-five microliters of vortexed beads were added to all wells
(standard and mice sera), plate sealed, and incubated overnight at 4 ◦C on rocker. The following
day the immunoassay procedure was established using Magpix PC, by creating a standard with
input cytokine concentrations as per assay to calculate the average of these and what is the expected.
Moreover, sample details are added with their dilution factors. After this, the plate was agitated
on plate shaker (450 rpm) for 10 mins at room temperature, and then ready to perform the analysis.
A quality control step was then performed, to check the file was created correctly for each cytokine
and review standard curves that must within their expected range for each cytokine.
2.6. Evaluation of CD8+ T Cells by Intracellular Cytokine Staining (ICS)
The CD8+ T cell response was assessed by ICS, detecting specific IFNγ and TNFα production
in stimulated peripheral blood mononuclear cells (PBMC). For that, PBMC on Day 50 (1 week after
the second boost) were collected from vaccinated and naïve mice. The PBMC cells were stimulated
with immunodominant Pb9 peptide for 12 h with a concentration of 1 µg/ml [29], as well as brefeldin
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A (BFA) (BD GolgiPlug™). To check the cell viability, aqua live/dead cell staining (Thermo Fisher
Scientific) was added. The CD3+ T cells were stained using the antibodies anti-mouse CD3 Alexa
Fluor® 700 (Clone: 17A2), anti-mouse CD8 conjugated with PE (Clone: 53-6.7), anti-mouse tumor
necrosis factor alpha (TNFα) APC (Clone: MP6-XT22), and anti-mouse interferon-gamma (IFNγ)
(Clone: XMG1.2). For the flow cytometry valuation was used a BD FACSCanto™ Flow Cytometer
(BD Biosciences, Oxford, UK). For data analysis the software FlowJo (Flowjo, Ashland, OR, USA) or
GraphPad Prism (Graphpad Software, Inc., San Diego, CA, USA) were applied.
2.7. Animals
Female inbred BALB/c (H-2d) and outbred CD1 (ICR) mice were used for the assessment of
immunogenicity and protection after challenge. Tuck-ordinary (TO) outbred mice were used for
parasite production and transmission. Mice were purchased from Harlan (UK). Transgenic parasites
were developed in Leiden University Medical Centre (LUMC) using 6-week old Swiss mice (Charles
River).
2.8. Ethics Statement
All animals and procedures were used in accordance with the terms of the UK Home Office
Animals Act Project License. Procedures were approved by the University of Oxford Animal Care
and Ethical Review Committee (PPL P9804B4F1). Animal experiments performed at LUMC were
approved by the Animal Experiments Committee of the Leiden University Medical Center (DEC
12042). The Dutch Experiments on Animals Act was established under European Guidelines (EU
Directive no. 86/609/EEC regarding the Protection of Animals used for Experimental and Other
Scientific Purposes).
2.9. Parasite Production
Wild type and transgenic parasites used to challenge mice were produced at the insectary of the
Jenner Institute. Female Anopheles stephensi mosquitoes were fed on infected BALB/c mice. Briefly,
exflagellation was first confirmed and mosquitoes were exposed to anaesthetized infected mice for
10 min. Mosquitoes were then maintained for 21 days in a humidified incubator at a temperature of
19–21 ◦C on a 12 h day–night cycle and fed with a fructose/PABA solution.
2.10. Parasites
The wild type (WT) reference line cl15cy1 of P. berghei ANKA [30] and the reporter PbANKA
parasite line PbGFP-Luccon (676m1cl1). PbGFP-Luccon parasite expresses a fusion protein of GFP
(mutant3) and firefly luciferase (LUC-IAV) under the constitutive eef1a promoter and is SM-free [31].
The reporter-cassette is integrated into the neutral 230p locus (PBANKA_030600). For details of
PbGFP-Luccon, see RMgmDB entry #29 (http://www.pberghei.eu/index.php?rmgm=29).
2.11. Generation of DNA Constructs and Genotyping of the Transgenic Parasites
To generate the transgenic parasites where the P. berghei trap gene (PBANKA_134980) coding
sequence (CDS) has been replaced by the CDS of P. falciparum trap (PF3D7_1335900), we used a
2-step GIMO transfection protocol [31,32]. In the first step we deleted the P. berghei trap CDS and
replaced it with the positive-negative selectable marker, to create a P. berghei trap deletion GIMO
line (PbANKA-TRAP GIMO). In order to this we generated pL2111 construct that is based on the
standard GIMO DNA construct pL0034 [31]. This construct contains the positive-negative (hdhfr:yfcu)
selection marker (SM) cassette, and was used to insert both the Pbtrap 5′ and 3′ gene targeting regions
(TR), encompassing the full length promoter and transcription terminators sequences respectively.
The construct was linearized using ApaI and NotI restriction enzymes outside of the 5′ and 3′ TRs
before transfection. The linear pL2111 DNA construct was introduced into PbGFP-Luccon parasites
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using standard methods transfection [30]. Transfected parasites were selected in mice by applying
positive selection by providing pyrimethamine in the drinking water [31]. Transfected parasites were
cloned by limiting dilution [33], resulting in the PbANKA-TRAP GIMO line (2564 cl3) (Figure S1).
Correct deletion of the P. berghei csp CDS was confirmed by diagnostic PCR-analysis on gDNA and
Southern analysis of pulsed field gel (PFG)-separated chromosomes as described [30]. Primers used
for PCR genotyping are listed in Table S1.
In the second step we replaced the positive-negative SM in the PbANKA-TRAP GIMO genome
with the CDS of P. falciparum trap by GIMO transfection to create the P. berghei transgenic TRAP
replacement lines. This was achieved by modifying the construct used in the first step (pL2111) to
generate pL2127 DNA construct; specifically, the hdfhr:yfcu SM cassette was removed and replaced with
P. falciparum trap CDS sequence (Figure S1). The P. falciparum trap CDS was amplified by PCR from P.
falciparum wild-type genome and was sequenced to ensure there were no mutations in the P. falciparum
trap CDS. The construct was linearized using ApaI and KasI restriction enzymes outside of the 5′ and
3′ TRs before transfection. This construct was used to transfect parasites of the PbANKA-TRAP GIMO
line (2564 cl3) using standard methods of GIMO-transfection [34]. Transfected parasites were selected
in mice by applying negative selection by providing 5-fluorocytosine (5-FC) in the drinking water
of mice [35]. Negative selection results in selection of chimeric parasites where the hdhfr:yfcu SM in
the trap locus of PbANKA-TRAP GIMO line is replaced by the CDS of P. falciparum TRAP. Selected
transgenic parasite was cloned by the method of limiting dilution [34]. Correct integration of the
constructs into the genome of chimeric parasites was analyzed by diagnostic PCR-analysis on gDNA
and Southern analysis of pulsed field gel (PFG) separated chromosomes as previously described [30].
Primers sequences used for generation of DNA constructs are shown in Table S2, and primers used
for PCR genotyping are listed in Table S1, while the expected PCR product sizes and the primer
numbers are listed in the table below (Table S3) the PCR analysis (Figure S2). This method creates
transgenic ‘gene replacement’ P. berghei parasites that do not contain P. berghei trap gene CDS but
express P. falciparum TRAP (PbANKA-PfTRAP(r)PbTRAP; 2632 cl1) under the control of the P. berghei
trap regulatory sequences.
2.12. Phenotyping of Reporter and Transgenic Parasites.
Growth of blood stages of the reporter and transgenic P. berghei parasites was determined
during the cloning period as described [30,34]. Feeding of A. stephensi mosquitoes, determination
of oocyst production, and sporozoite collection were performed as previously described [34].
Expression of PfTRAP antigen in sporozoites of the transgenic parasites was analyzed by
immunofluorescence-staining assay (IFA), using serum from vaccinated mice with PfTRAP or PbTRAP
as a control; diluted 50 times. Purified sporozoites were fixed with 4% paraformaldehyde in PBS
for 20 min on ice, then washed three times with PBS and blocked with 20 µL 10% FCS + 1% BSA in
PBS for 30 min at room temperature. The excess blocking medium was removed, followed by the
addition of 20 to 25 µL of the diluted serum containing the primary antibody in 10% FCS + 1% BSA in
PBS (blocking medium) for 1 to 2 h at room temperature or overnight at 4 ◦C. After incubation the
primary antibody was removed and the slides washed three times with PBS, followed by the staining
with the secondary antibody (Alexa Fluor® 488 Goat Anti-Mouse IgG from life technologies, Cat#
A-11001) diluted 800 times in 10% FCS + 1% BSA in PBS (blocking medium) for one hour at room
temperature. After washing three times with PBS, nuclei were stained with 2% Hoechst-33342 (Cell
Signaling Technology #4082S) in PBS for 10 min at room temperature, washed twice with PBS and
left to air-dry, this followed by adding Fluorescence Mounting Medium (Dako, code S3023) before
complete dry out. Cover slips were mounted onto the slides, and the slides were sealed with nail polish
and left to dry overnight in dark. The parasites in both blue and green channels were analyzed using a
DMI-300B Leica fluorescence microscope and images processed using ImageJ software (Figure S3).
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2.13. Efficacy Studies: Determination of Liver Parasite Liver Load by Real Time Imaging and Determination
Prepatent Period (after Challenge of Immunized Mice with Transgenic Sporozoites)
To determine the efficacy of the liver-stage vaccines, transgenic P. berghei infected A. stephensi
mosquitoes were dissected 21 days post-feed and salivary gland sporozoites resuspended in RPMI-1640
media (Sigma Aldrich). One-thousand transgenic sporozoites were injected i.v. into the tail vain per
mouse, into both vaccinated and naïve controls (Figure S4).
2.14. Statistical Analysis and Parasitemia Prediction
Parasitemia levels in mice infected with P. bergei-PfTRAP were checked daily until reaching
infection of 1% in blood-stage. For the parasitemia prediction a linear regression model was used
as previously described [10,19,36–38]. In summary, blood from infected mice were collected daily
after the fourth day post challenge and blood smears were stained with Giemsa and 1000 blood cells
counted for each mouse sample. The logarithm to base 10 for percentage of parasitemia was plotted
against the time after challenge and Prism 5 for Mac OS X (GraphPad Software, La Jolla, CA, USA)
was used for generating a linear regression model on the linear part of the blood-stage growth curve.
For all other statistical analyses, GraphPad Prism software version 5.0 for Max OS was also used.
For the comparison of two normally distributed groups it was used unpaired t-test, although for
comparing of two non-parametric groups a Mann–Whitney rank test was applied. When more than
two groups were existing, non-parametric data was compared using Kruskal–Wallis test with Dunn’s
multiple comparison post-test, whereas normally distributed data were analyzed by one-way ANOVA
with Bonferroni’s multiple comparison post-test. The value of p < 0.05 was considered statistically
significant (* p < 0.01, ** p < 0.001, *** p < 0.0001).
3. Results
3.1. DOPS Promotes a Th1 Response in TRAP-Vaccinated BALB/c Mice
The most used adjuvants in vaccine formulation for infectious diseases remain aluminum based.
However, alum is inefficient at inducing Th1 immunity as responses are normally biased towards Th2
cytokines. However, for diseases such as malaria, vaccine formulations that induce Th1 responses are
certainly preferred. In addition, induction of CD8+ T cells is also important, another characteristic
that may not be typical for alum [17,19–23]. We therefore wanted to address, whether DOPS may be
able to induce Th1 responses and aimed to directly compare the adjuvants activity of DOPS to alum.
To this end, BALB/c mice were vaccinated i.m. with recombinant TRAP protein from P. falciparum
formulated in alum, DOPS or PBS on days 0, 21, and 42. For assessment of Th1 and Th2 cell induction,
serum samples from one week after the third immunization were collected and checked by multiplex
assay. As seem in the Figure 1, those cytokines related to Th1 (IFNγ and TNFα) were increased in mice
vaccinated with TRAP + DOPS compared to mice vaccinated with TRAP + alum or TRAP formulated
in PBS. In contrast, IL-4 production was increased in mice vaccinated with TRAP + alum compared to
mice vaccinated with TRAP + DOPS. Thus, as perhaps expected, alum induced a cytokine response
dominated by IL-4 while DOPS induced a cytokine responses dominated by IFNγ and TNFα.
TRAP was also displayed on CuMVtt-VLPs and tested with or without DOPS. Conjugation of
antigens to VLPs containing RNA usually enhances Th1 responses and may represent an important
step within the system to drive immune responses towards Th1. We therefore conjugated TRAP to
CuMVtt and vaccinated BALB/c mice with CuMVtt-TRAP, with CuMVtt-TRAP + DOPS or only TRAP
protein. As in the previous experiment, we assessed presence of Th1 and Th2 cytokines in the serum
one week after the third boost. As seen in the Figure 1, mice vaccinated with CuMVtt-TRAP in PBS
exhibited increased serum levels of IFNγ, TNFα, and IL-4. In contrast, CuMVtt-TRAP formulated with
DOPS adjuvants exhibited highest serum levels of IFNγ and TNFα paralleled by a decrease in the
IL-4 response. These findings support use of DOPS in combination with VLPs for the development of
vaccines against malaria and other infectious diseases, as they require Th1 rather than Th2 responses.
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3.2. Antibody Production by Vaccinated BALB/c Mice 
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responses. However, some studies claim that antibodies against TRAP are also important and have 
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Figure 1. Assessment of CD4+ T cells polarization. Mice were immunized once every three weeks.
One week after the third vaccination the mice were bled to obtain sera for cytokine analysis. To evaluate
cytokine production, TNFα, IFNγ (Th1 and CTL), and IL-4 (Th2) were measured by multiplex assays
MHSTCMAG-70K kit. Also, for experimental control, standard curves were made of each cytokine and
compared with the expected concentration provided by the kit, as seen in the figure. The results were
analyzed using GraphPad Prism software applied to assess the means of the groups by unpaired t-tests.
Note: *** p-value < 0.0001; ** p-value < 0.001; * p-value < 0.01. MFI = Median Fluorescence Intensity.
3.2. Antibody Produ tion by Vaccinated BALB/c Mice
Protection induced by vaccination against TRAP is thought to be based on induction of T cell
responses. However, some studies claim that antibodies against TRAP are also important and
have to be c s dered when developi g TRAP-based Vaccines. We therefore assessed the humoral
immunogenicity of all groups mentioned above. As seen in Figure 2, after a single vaccin tion and lso
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subsequently, the best responder group was vaccinated with CuMVtt-TRAP + DOPS. Thus, CuMVtt
formulated in DOPS induced the strongest Th1 as well as antibody response.
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Figure 2. Kinetics of antibody production in BALB/c mice. The figure shows IgG total of all groups of
mice bled three weeks after each vaccination, specifically on Days 21, 42, and 59. As seen in the figure,
the mice that best responded were those vaccinated with PfTRAP coupled with VLP. Also, when the
VLP-PfTRAP was mixed with DOPS adjuvants, it provided an improvement of the antibody response
with highly statistical significant (p = 0.0001) when compared with the control group.
The subclass of the induced antibodies is important as many studies show that IgG2a and IgG2b
are the most protective subclasses in animal models. Also in humans, the IgG3 subclass (usually
associated with IgG2b in mice) has been associated with protection against malaria [39–45]. As shown
in Figure 3, the group vaccinated with TRAP formulated in alum exhibited IgG1 as the dominant IgG
subclass. In contrast, the group vaccinated with TRAP formulated with DOPS alone or in combination
with VLP predominantly produced IgG2a and IgG2b. TRAP formulated in DOPS, in particular
when associated to CuMVtt, induced IgG responses dominated by the most protective subclasses,
IgG2a and IgG2b.
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Figure 3. Assessment of IgG subtype in BALB/c mice. The antibody subclasses were tested on day
59 of the immunized mice. VLP-conjugate vaccines induced the more protective isotypes IgG2a and
IgG2b compared to TRAP formulated alum. In oth r hand, he group of mice vaccinated with TRAP
+ alum ind ced IgG1 subtype, as exp cted. Note: *** p-value < 0.0001; * p-value < 0.01.
3.3. TRAP-CuMVtt+DOPS Induces Best Protection Against Infection with P. Bergei Expressing PfTRAP
The most important and stringent way to assess the ability of vaccine formulations to induce
protective immune responses is to assess actual protectio agai st infection. However, P. falciparum
does not infect mice. We therefore, constructed a transgenic P. berghei replacement mutant expressing
Diseases 2018, 6, 107 10 of 15
TRAP of P. falciparum instead of its own protein. This transgenic parasite showed efficient capacity to
infect and replicate in mice. To test vaccine efficacy, BALB/c mice were immunized with TRAP alone,
TRAP formulated in alum or DOPS or TRAP-CuMVtt alone or formulated in DOPS. Two weeks after
the third vaccination, immunized and naïve mice were infected with the transgenic P. berghei expressing
PfTRAP. After infection, mice were assessed for parasite load daily until 1% of all erythrocytes were
infected. At this point, mice had to be euthanized according to the terms of United Kingdom Home
Office Animals Act Project License. As seen in the Figure 4 the most resistant group of mice was
the one vaccinated with VLP-TRAP + DOPS. The delay of parasitemia seen in these mice correlates
with the fact that they mounted the best immune response and shows that TRAP coupled to CuMVtt
formulated in DOPS might be a promising vaccine candidate.
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Figure 4. Survival curve and comparative analysis of parasitemia in BALB/c mice infected with
Plasmodium berghei replacement expressing TRAP of P. falciparum (PfTRAP). (A) Kaplan–Meyer survival
curve that shows the time when the mice reach 1% or more of the erythrocytes infected. (B) Number
of days until mice have more than 1% of erythrocytes infected and the comparison of the groups.
The experiment did not induce sterile protection, but immunization with PfTRAP-VLP plus DOPS
conferred significant protection (p = 0.0005) when compared to the group control vaccinated with TRAP
only. Also, infection in mice vaccinated with PfTRAP-VLP was significantly delayed when compared
to the group vaccinated with only TRAP (p = 0.0354). *** p-value < 0.0001; * p-value < 0.01.
3.4. Assessing the Efficacy of Vaccine Formulated with TRAP-VLP + DOPS in CD1 Mice
BALB/c is a well-tested mouse model for malaria vaccine development. However, it is important
to test candidate vaccine formulations with different mu ine strai s, in particular also utbr d stain .
For this reason, we confirmed the pr tective capacity of th most p omi ing vaccine formulations
(CuMVtt-TRAP + DOPS nd CuMVtt-TRAP in PBS compared to TRAP alone) in CD1 outbred mic .
As seen above in BALB/c mice, the humoral immune response mounted by CD1 mice v ccinated with
VLP-TRAP + DOPS was higher than the group of mice v ccinated with TRAP-VLP without adjuvant,
as well as the mice vaccinated with TRAP only (Figure 5).
In ditio to humoral im unity, ellular immune responses w re also assessed. The most
advanced vaccine against malaria is the RTS,S formulated in AS01, which induces strong and protective
antibodies as well as CD4+ T cell responses but fails to induce significant CD8+ T cell responses.
We therefore assessed CD8+ T cell responses in mice vaccinated with the different TRAP formulations
(Figure 6). TRAP coupled to CuMVtt VLPs formulated in DOPS induced the strongest CD8+ T cell
responses, indicating that this vaccine formulation may be a promising addition to RTS,S/AS01, as it
further promotes cellular immunity.
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Figure 5. Kinetics of antibody production in CD1 mice. CD1 mice were immunized once every three
weeks with TRAP, VLP-TRAP, or VLP-TRAP formulated with DOPS. Blood was taken on Days 21, 42,
and 59 and serum antibody levels were determined. Total IgG levels against TRAP are shown in this
figure; the group of mice vaccinated with PfTRAP coupled with VLP, as well as when the VLP-PfTRAP
was mixed with DOPS adjuvants induced significantly antibody response when compared with the
control group. Note: *** p-value < 0.0001; ** p-value < 0.001; * p-value < 0.01.
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Figure 6. A se sment of TRAP-specific CD8+ T cell responses in CD1 mice. As described in Figure 1,
mice were immunized thr e times every thr e w eks and bled on day 50 (eight days after the third
va cination) and the PBMC ce ls were sti ulated with i munodominant Pb9 peptide to a se s
production of IFNγ and T Fα by 8+ T ce ls. As s en in the figure above, the group of mice
va cinated with VLP-TRAP + DOPS was able to produce more IFNγ and TNFα than the groups of
mice va cinated with TRAP protein either VLP-TR P. t : *** - l 0.0001; ** p-value < 0.001.
To ssess vaccine-induced protection, CD1 mice were infected with transgenic P. berghei expressing
TRAP of P. falciparum, as described above. As seen in the Figure 7, mice vaccinated with CuMVtt-TRAP
+ DOPS showed a delay in parasitemi and even sterile protection was observed in some. To consider
protecti n as sterile, mice should not have any erythr cytes infected until 14th day after challenge.
The mice were observed for an additional two weeks to check for any signal of disease. At the end of
each experiment the mice were sacrificed.
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i r 7. Kaplan–Meyer survi al curve showing when t e CD1 mice reached 1% or more of parasitemia
or did not have any infected erythrocyt s, which is considered to be sterile protection. The only group
of mice showing so e sterile protection was the group of mice vaccinated with PfTRAP-VLP plus
DOPS (red line). Parasite load was counted daily in blood smears until 14 days after challenge and kept
for another two wee s under observation to check for signals of disease. The group of mice immunized
with PfTRAP-VLP plus DOPS con erred significant protection (p = 0.0001) when compared to the group
control vaccinated with TRAP ly.
These data underscore the potency of CuMVtt-TRAP + DOPS as it is known that sterile protection
is hard to achieve and usually only happens when using combinations of different antigens.
4. Discussion
In the present study, we assessed immunogenicity and protective capacity of PfTRAP formulated
in DOPS or alum and studied the added value of coupling the antigen to CuMVtt-VLPs. To assess the
protective capacity of the different vaccine formulations, we constructed a mutant P. berghei parasite by
replacing its own TRAP by the TRAP of P. falciparum. This resulted in a malaria parasite able to replicate
in mice but expressing TRAP of P. falciparum. Our results clearly show that PfTRAP conjugated to
VLPs and formulated in DOPS induces the best T cell responses and the highest antibody responses
dominated by protective isotypes. The same vaccine candidate also induced best protection in BALB/c
inbred and CD1 outbred mice.
Most currently used adjuvants, such as Alum or MF59, are unable to promote strong Th1 responses
but rather enhance Th2 responses. However, CTL responses usually go together with Th1 responses
which therefore are not promoted by this type of classical adjuvants. Here we show that DOPS is
able to promote both strong Th1 and CTL responses as well as the formation of IgG2a and IgG2b
subclass antibodies. Phosphatidylserines are an indicator of cell death as they are expressed on the
outer surface of apoptotic cells. As a consequence, they are categorized as prominent danger-associated
molecular patterns (DAMPs). Whilst specific mechanisms of the adjuvant property of DOPS remain to
be further elucidated, it will be interesting to further study this “danger signal” activity and elucidate
its mechanism compared to alum. Indeed, it has been hypothesized in a recent report that a possible
mechanism of alum relates to the induction of DAMP’s released by viable cells after phagocytosis of
aluminum-based adjuvants [46].
VLPs, in particular VLPs loaded with RNA such as CuMVtt, are potent inducers of IgG responses
dominated by the IgG2a isotype as well as Th1 and CTL responses. The high IgG responses are due to
the repetitive nature of the VLP-surface: pathogen-associated molecular patterns (PAMPs), while the
IgG2a and Th1/CTL responses are caused by the RNA spontaneously packaged by the VLPs during
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expression in E. coli. As such, a rational approach was sought in combining drug delivery concepts
(i.e., VLP) in combination with second generation adjuvant (i.e., immunomodulators such as DOPS)
functioned to provide a means by which immune activation could be better achieved for a vaccine to
confer enhanced protection.
Strikingly, DOPS was not only able to significantly increase the IgG2a responses but also Th1 and
CD8+ T cell responses. The latter may be of particular interest, as it is notoriously difficult to induce
CD8+ T cell responses, in particular in humans. It will therefore be of interest whether these results
can be confirmed in human clinical studies. This would not only impact the design of antiparasitic
vaccines such as described here but extend to the field of cancer vaccination, where lack of efficient
induction of tumor-specific CD8+ T cells remains a well-known problem.
Supplementary Materials: The following are available online http://www.mdpi.com/2079-9721/6/4/107/s1,
Figure S1: Strategy to generate a chimeric P. berghei parasite line expressing P. falciparum TRAP. Figure S2. Genotype
analyses of the chimeric P. berghei parasite line expressing P. falciparum TRAP. Figure S3. Phenotype analyses and
fitness of the chimeric P. berghei parasite line expressing P. falciparum TRAP. Figure S4. In vivo imaging. Table S1.
Primers for genotyping the transgenic parasite line. Table S2. Primers for generation of DNA construct. Table S3.
Oocyst and sporozoites production for PfTRAP(r)PbTRAP transgenic parasite (line 2632 cl1) in comparison to the
WT-GFP: Luc P. berghei (line 676m1 cl1).
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